UNASSIGNED: Statin therapy targeting reduction of low-density lipoprotein @entity165 (LDL-C) decreases the risk of @entity301 ( @entity301 ) and all-cause mortality. However, a substantial number of cases of @entity301 are not prevented and residual risk factors remain unsettled. A high @entity412 (TG) level is considered to be an important and residual risk factor. @entity407 is a condition in which TG-rich chylomicron remnants are increased during the postprandial period and hypertriglycedemia is protracted. @entity407 evokes @entity731 during the postprandial period. Several prospective studies have revealed that nonfasting serum TG levels predict the incidence of @entity301 . Values of TG, remnant lipoprotein @entity165 , and remnant lipoprotein TG after fat loading were significantly higher in @entity6 @entity1 with insulin resistance than in @entity6 @entity1 without insulin resistance. @entity409 is an initial process of @entity731 and it contributes to the pathogenesis of @entity301 . @entity407 (postprandial @entity2298 ) is involved in the production of proinflammatory cytokines, recruitment of neutrophils, and generation of oxidative stress, resulting in @entity409 in healthy subjects, @entity6308 @entity1 , or type 2 @entity6 @entity1 . Effective treatment has not been established till date. @entity3709 or @entity9539 significantly decrease postprandial TG elevation and postprandial @entity409 . @entity3709 or @entity9539 added to statin therapy reduce serum TG levels and result in good outcomes in @entity1 with @entity301 . In conclusion, postprandial @entity407 is an important and residual risk factor especially in @entity1 with @entity1720 ( @entity209 ) and @entity6 . Further studies are needed to establish effective treatment.

XXXX as a potential residual risk factor.

@entity407 :: ('MESH:D006949', 'Disease') :: ['Postprandial hyperlipidemia', 'hyperlipidemia'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes', 'diabetes mellitus'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction', 'Endothelial dysfunction'] @entity6308 :: ('MESH:D064250', 'Disease') :: ['hypertriglyceridemic'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity3709 :: ('MESH:C108606', 'Chemical') :: ['Ezetimibe'] @entity9539 :: ('MESH:D015525', 'Chemical') :: ['omega-3 fatty acids'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherogenesis'] @entity1720 :: ('MESH:D007333', 'Disease') :: ['insulin resistance syndrome'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity407 :: (MESH:D006949,Disease) :: ['Postprandial hyperlipidemia']
